LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 5 of total 5

Search options

  1. Article ; Online: TOWARD AN IMAGING-CENTRIC DEFINITION OF NONPARANEOPLASTIC AUTOIMMUNE RETINOPATHY.

    Xu, Lucy T / Zheng, Andrew / Shantha, Jessica G / Yeh, Steven / Yan, Jiong / Hubbard, G Baker / Patel, Purnima S / Waltuck, Jonathan / O'Keefe, Ghazala / Jain, Nieraj

    Retina (Philadelphia, Pa.)

    2024  Volume 44, Issue 5, Page(s) 868–877

    Abstract: Purpose: To explore characteristic imaging features of nonparaneoplastic autoimmune retinopathy (npAIR) to augment diagnostic criteria.: Methods: This is a retrospective cohort study of patients with npAIR evaluated at the Emory Eye Center between ... ...

    Abstract Purpose: To explore characteristic imaging features of nonparaneoplastic autoimmune retinopathy (npAIR) to augment diagnostic criteria.
    Methods: This is a retrospective cohort study of patients with npAIR evaluated at the Emory Eye Center between 2013 and 2019. Multimodal fundus images were evaluated to characterize the evolution of the disease.
    Results: Twenty-one eyes of 12 patients were classified as having npAIR. Five patients (42%) were female, with median (range) age of 59 years (45-85 years). Median baseline visual acuity was 20/30 (20/20 to hand motions). Disease was asymmetric in 11 patients (92%). Common imaging findings included absence of bone spicules (86% of affected eyes), presence of attenuated vessels (86%), and speckled hypoautofluorescence in perimacular and perivenular regions. Three eyes were noted to present early with subtle splotchy fundus autofluorescence abnormality, ultimately developing characteristic speckled perimacular hypoautofluorescence. On optical coherence tomography, 18 eyes (86%) had loss of outer retinal bands with relative foveal sparing and a tapered transition zone.
    Conclusion: Many eyes with npAIR exhibit a subacute, asymmetric, generalized photoreceptor degeneration featuring outer retinal atrophy with relative foveal sparing, retinal vascular attenuation, absence of bone spicules, and speckled hypoautofluorescence often in a perimacular and perivenular distribution. Findings of this study augment diagnostic criteria to improve specificity and accessibility of testing for npAIR.
    MeSH term(s) Humans ; Female ; Middle Aged ; Retrospective Studies ; Male ; Aged ; Tomography, Optical Coherence/methods ; Autoimmune Diseases/diagnosis ; Fluorescein Angiography/methods ; Aged, 80 and over ; Visual Acuity ; Retinal Diseases/diagnosis ; Retinal Diseases/physiopathology ; Fundus Oculi
    Language English
    Publishing date 2024-01-03
    Publishing country United States
    Document type Journal Article
    ZDB-ID 603192-4
    ISSN 1539-2864 ; 0275-004X
    ISSN (online) 1539-2864
    ISSN 0275-004X
    DOI 10.1097/IAE.0000000000004036
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1724: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: A Safety Analysis of Programmed Death 1 Pathway Inhibitors in Patients With Solid Tumor Malignancies and Preexisting Autoimmune Disease.

    Higgins, Jordyn Paige / Trinh, Anh Viet / Watson, Marley L / Beardslee, Tyler / Goyal, Subir / Kudchadkar, Ragini / Pakkala, Suchita / Waltuck, Jonathan / Momary, Kathryn / Byers, Kristina F

    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases

    2022  Volume 28, Issue 7, Page(s) 338–345

    Abstract: Objective: The aim of this study was to characterize the safety of programmed death 1 inhibitors in patients with preexisting autoimmune disease.: Methods: A medical records review study was conducted on adults with solid tumor malignancies who ... ...

    Abstract Objective: The aim of this study was to characterize the safety of programmed death 1 inhibitors in patients with preexisting autoimmune disease.
    Methods: A medical records review study was conducted on adults with solid tumor malignancies who received ≥1 dose of pembrolizumab or nivolumab at Emory Healthcare from September 4, 2014 until December 31, 2019. All autoimmune patients were included (n = 77), whereas the nonautoimmune patients were randomized and the first 156 patients were included in a 2:1 ratio to autoimmune patients. The primary objective was the comparison of incidence of immune-related adverse events (irAEs) between patients with preexisting autoimmune disease and those without. Secondary objectives included irAE characterization, irAE treatment, and survival analyses.
    Results: Preexisting autoimmune disease was controlled in all of the autoimmune patients before immunotherapy initiation. The rate of irAE was 32.7% in the nonautoimmune group and 42.9% in the autoimmune group (odds ratio, 0.65; 95% confidence interval, 0.37-1.14; p = 0.130). In the patient population diagnosed with a rheumatologic autoimmune disease, 23.81% of irAEs were considered to be a flare of their preexisting autoimmune disease. Less patients in the autoimmune group experienced a grade ≥3 irAE (21.21% vs 37.25%, p = 0.379) and received systemic corticosteroids (54.55% vs 67.35%, p = 0.241) for the treatment of the irAE.
    Conclusions: These results suggest that pembrolizumab and nivolumab can be safely administered in patients with controlled preexisting autoimmune diseases without a significant increase in irAE compared with patients without autoimmune diseases. Inclusion of patients with preexisting autoimmune diseases in prospective clinical trials is warranted.
    MeSH term(s) Adrenal Cortex Hormones/therapeutic use ; Adult ; Antineoplastic Agents, Immunological/adverse effects ; Autoimmune Diseases/complications ; Autoimmune Diseases/drug therapy ; Humans ; Neoplasms/drug therapy ; Nivolumab/adverse effects ; Programmed Cell Death 1 Receptor ; Prospective Studies ; Retrospective Studies
    Chemical Substances Adrenal Cortex Hormones ; Antineoplastic Agents, Immunological ; Programmed Cell Death 1 Receptor ; Nivolumab (31YO63LBSN)
    Language English
    Publishing date 2022-06-08
    Publishing country United States
    Document type Journal Article ; Randomized Controlled Trial
    ZDB-ID 1283266-2
    ISSN 1536-7355 ; 1076-1608
    ISSN (online) 1536-7355
    ISSN 1076-1608
    DOI 10.1097/RHU.0000000000001863
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4815: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Book: Recent developments in vasculitis

    Waltuck, Jonathan

    1995  

    Abstract: Producer) Dr. Waltuck defines vasculitis as "inflammation of blood vessel walls, leading to perturbation of blood flow, with ischemia, infarct or hemorrhage". It may involve all sizes of arteries as well as some veins. Classification schemes are ... ...

    Institution Emory Medical Television Network
    Author's details [presented by] the Emory Medical Television Network, Emory University School of Medicine of the Robert W. Woodruff Health Sciences Center
    Abstract (Producer) Dr. Waltuck defines vasculitis as "inflammation of blood vessel walls, leading to perturbation of blood flow, with ischemia, infarct or hemorrhage". It may involve all sizes of arteries as well as some veins. Classification schemes are artificial because there is considerable overlap and many cases defy classification attempts. It is important to consider the syndromes and entities that are "vasculitis imitators". Anti-phospholipid syndrome, atrial myxoma, infective endocarditis, TIPand DIC and cholesterol emboli syndrome. Dr. Waltuck continues with some interesting remarks about the most common syndromes: Temporal arteritis, Polymyalgia rheumatica, Wegener's granulomatosis and Polyarteritis nodosa. He concludes with a review of the recently introduced ANCA and some comments about therapies for the vasculitic syndromes.
    MeSH term(s) Vasculitis
    Language English
    Size 1 videocassette (56 min.) :, sd., col. ;, 1/2 in.
    Publisher The University
    Publishing place Atlanta, GA
    Document type Book
    Note Approved for CE credit.
    Database Catalogue of the US National Library of Medicine (NLM)

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  4. Article: Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial.

    Kremer, Joel / Genovese, Mark / Cannon, Grant W / Caldwell, Jacques / Cush, John / Furst, Daniel E / Luggen, Michael / Keystone, Ed / Bathon, Joan / Kavanaugh, Arthur / Ruderman, Eric / Coleman, Patricia / Curtis, David / Kopp, Elliott / Kantor, Seth / Weisman, Michael / Waltuck, Jonathan / Lindsley, Herbert B / Markenson, Joseph /
    Crawford, Bruce / Fernando, Indra / Simpson, Karen / Strand, Vibeke

    The Journal of rheumatology

    2004  Volume 31, Issue 8, Page(s) 1521–1531

    Abstract: Objective: To obtain additional safety and efficacy data on leflunomide (LEF) treatment in combination with methotrexate (MTX) therapy in an open-label extension study in patients with rheumatoid arthritis (RA).: Methods: Following a 24 week, ... ...

    Abstract Objective: To obtain additional safety and efficacy data on leflunomide (LEF) treatment in combination with methotrexate (MTX) therapy in an open-label extension study in patients with rheumatoid arthritis (RA).
    Methods: Following a 24 week, randomized, double-blind trial of adding placebo (PLA) or LEF to stable MTX therapy, patients could enter a 24 week extension. Subjects randomized to LEF and MTX continued treatment [(LEF/LEF) + MTX]. Subjects randomized to PLA and MTX switched to LEF (10 mg/day, no loading dose) and MTX [(PLA/LEF) + MTX]. The double-blind regarding initial randomization was maintained.
    Results: For subjects in the extension phase, American College of Rheumatology 20% (ACR20) responder rates for the (LEF/LEF) + MTX group were maintained from Week 24 (57/96, 59.4%) to Week 48 (53/96, 55.2%). ACR20 responder rates improved in patients switched to LEF from PLA at Week 24 [(PLA/LEF) + MTX] from 25.0% (24/96) at Week 24 to 57.3% (55/96) at Week 48. Patients in the extension who switched from PLA to LEF without a loading dose exhibited a lower incidence of elevated transaminases compared to patients initially randomized to LEF. Diarrhea and nausea were less frequent during the open-label extension in patients who did not receive a LEF loading dose.
    Conclusion: Response to therapy was maintained to 48 weeks of treatment in patients who continued to receive LEF and MTX during the extension. Importantly, ACR20 response rates after 24 weeks of LEF therapy were similar between patients switched from PLA to LEF without loading dose, and those who received a loading does of LEF (100 mg/day x 2 days) at randomization. Fewer adverse events were reported in patients switched to LEF without a loading dose.
    MeSH term(s) Antirheumatic Agents/adverse effects ; Antirheumatic Agents/therapeutic use ; Arthritis, Rheumatoid/drug therapy ; Double-Blind Method ; Drug Therapy, Combination ; Humans ; Immunosuppressive Agents/adverse effects ; Immunosuppressive Agents/therapeutic use ; Isoxazoles/adverse effects ; Isoxazoles/therapeutic use ; Methotrexate/adverse effects ; Methotrexate/therapeutic use ; Retreatment ; Treatment Outcome
    Chemical Substances Antirheumatic Agents ; Immunosuppressive Agents ; Isoxazoles ; leflunomide (G162GK9U4W) ; Methotrexate (YL5FZ2Y5U1)
    Language English
    Publishing date 2004-08
    Publishing country Canada
    Document type Clinical Trial ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 194928-7
    ISSN 1499-2752 ; 0315-162X
    ISSN (online) 1499-2752
    ISSN 0315-162X
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1168: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 135: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial.

    Kremer, Joel M / Genovese, Mark C / Cannon, Grant W / Caldwell, Jacques R / Cush, John J / Furst, Daniel E / Luggen, Michael E / Keystone, Ed / Weisman, Michael H / Bensen, William M / Kaine, Jeffrey L / Ruderman, Eric M / Coleman, Patricia / Curtis, David L / Kopp, Elliot J / Kantor, Seth M / Waltuck, Jonathan / Lindsley, Herbert B / Markenson, Joseph A /
    Strand, Vibeke / Crawford, Bruce / Fernando, Indra / Simpson, Karen / Bathon, Joan M

    Annals of internal medicine

    2002  Volume 137, Issue 9, Page(s) 726–733

    Abstract: Background: Disease-modifying antirheumatic drugs may confer greater benefits when combined with the antimetabolite methotrexate.: Objective: To evaluate the efficacy and safety of leflunomide versus placebo when added to ongoing, stable-dose ... ...

    Abstract Background: Disease-modifying antirheumatic drugs may confer greater benefits when combined with the antimetabolite methotrexate.
    Objective: To evaluate the efficacy and safety of leflunomide versus placebo when added to ongoing, stable-dose methotrexate therapy in patients with persistently active rheumatoid arthritis.
    Design: 24-week, multicenter, randomized, double-blind, placebo-controlled trial.
    Setting: 20 centers in the United States and Canada.
    Patients: Patients with persistent rheumatoid arthritis, as defined by American College of Rheumatology (ACR) criteria, despite receiving methotrexate for at least 6 months.
    Intervention: Leflunomide or matching placebo added to existing methotrexate therapy.
    Measurements: The primary efficacy variable was the rate of achievement of 20% improvement in ACR criteria (ACR20) at the end of the study. The Health Assessment Questionnaire Disability Index was assessed at each visit, and the Medical Outcomes Study 36-Item Short Form was completed as an end point analysis.
    Results: In the leflunomide and placebo groups, 46.2% and 19.5% of patients, respectively, met ACR20 criteria at 24 weeks (P < 0.001). Clinical improvement was demonstrated by statistically significant mean changes in individual components of the ACR20 response criteria. Discontinuation rates were similar in both treatment groups (23.1% in the leflunomide group and 24.8% in the placebo group), as were the overall incidences of adverse events (89.2% vs. 89.5%, respectively). Adverse events were predominantly mild or moderate.
    Conclusions: Combination therapy with leflunomide and methotrexate provides statistically significant clinical benefit in patients with active rheumatoid arthritis who are receiving methotrexate therapy. Leflunomide plus methotrexate is generally well tolerated and can be used safely with appropriate liver enzyme and hematologic monitoring.
    MeSH term(s) Adult ; Aged ; Anti-Inflammatory Agents, Non-Steroidal/adverse effects ; Anti-Inflammatory Agents, Non-Steroidal/therapeutic use ; Antimetabolites/adverse effects ; Antimetabolites/therapeutic use ; Arthritis, Rheumatoid/drug therapy ; Diarrhea/chemically induced ; Disability Evaluation ; Double-Blind Method ; Drug Therapy, Combination ; Female ; Humans ; Isoxazoles/therapeutic use ; Leflunomide ; Liver Function Tests ; Male ; Methotrexate/adverse effects ; Methotrexate/therapeutic use ; Middle Aged ; Placebos ; Quality of Life ; Surveys and Questionnaires ; Treatment Outcome
    Chemical Substances Anti-Inflammatory Agents, Non-Steroidal ; Antimetabolites ; Isoxazoles ; Placebos ; Leflunomide (G162GK9U4W) ; Methotrexate (YL5FZ2Y5U1)
    Language English
    Publishing date 2002-11-05
    Publishing country United States
    Document type Clinical Trial ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 336-0
    ISSN 1539-3704 ; 0003-4819
    ISSN (online) 1539-3704
    ISSN 0003-4819
    DOI 10.7326/0003-4819-137-9-200211050-00007
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.178/2: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top